Novo Nordisk announces a $675 US list price for Wegovy, Ozempic and Rybelsus effective January 2027

Novo Nordisk said on February 24, 2026 that it will lower the US list price — the wholesale acquisition cost — of Wegovy (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic (semaglutide) injection 0.5 mg, 1 mg and 2 mg, and Rybelsus (semaglutide) tablets 7 mg and 14 mg to $675 a month, effective January 1, 2027 ^[1]. That is a cut of roughly 50% for Wegovy and about 35% for Ozempic, and it applies to all doses of those medicines ^[1].

For context, the two Wegovy products currently carry list prices of around $1,350 a month, while the diabetes products sit near $1,027 ^[3]. Novo says the change is aimed at people whose out-of-pocket costs are calculated from list price, such as those in high-deductible health plans or with coinsurance benefit designs ^[1]. "The new $675 list price is a proactive move, specifically designed to help patients whose out-of-pocket costs are linked to list price," said Jamey Millar, Novo Nordisk's executive vice president of US operations ^[2]. Millar told CNBC that some commercially insured patients pay as little as $25 a month in "only the best of circumstances," while people in high-deductible plans pay "more or less the full list price" until the deductible is met, and others have 25% to 33% coinsurance tied to list ^[3].

Importantly, the company says the change does not affect direct-to-patient, self-pay prices ^[1]. Those cash prices already sit far below list: Novo sells Wegovy for about $349 on its own site ^[2], and its self-pay range runs roughly $149 to $499 a month depending on the product and dose ^[3].

The timing lines up with the January 1, 2027 start of negotiated Medicare prices for the same drugs under the Inflation Reduction Act ^[2]. CNBC reported those negotiated Medicare prices will be $274 a month for Wegovy, Ozempic and Rybelsus ^[3].

Why it matters for patients

List price is not what most people pay, but it is what many insurance formulas use. If your plan charges coinsurance — a percentage of the drug's price — or you have not met a deductible, a lower list price can translate into a smaller pharmacy bill starting in 2027 ^[1][3]. If you pay a flat copay, or you already buy through a cash-pay channel, the announcement changes little ^[4].

Benefits consultants at Mercer expect Novo to offset the lower list price by reducing rebates, which would mean "no meaningful change in net costs after rebates" for employers, though members paying coinsurance rather than a flat copay may see lower costs at the counter ^[4]. Mercer also warned that patients could hit temporary supply delays around January 1, 2027 if retail pharmacies trim inventory ahead of the price change, something that has happened with past price cuts ^[4].

Analysts were measured. Citi's Geoffrey Meacham said the cut likely benefits only a relatively small share of new prescriptions compared with cash-pay channels, which hold "an overwhelming share" ^[2]. Bernstein's Courtney Breen said it "isn't a silver bullet for Novo" and does not amount to a price war, citing the White House pricing deal as a "soft-floor for the next three years" ^[2].

Novo used the announcement to press its case against compounded copies, saying supply of all doses is fully available nationwide and "there is no reason for patients to gamble with their health with knock-off products produced by compounders" ^[1]. Reuters notes Novo and Eli Lilly still face competition from cheaper compounded versions sold through telehealth platforms such as Hims & Hers, which are permitted to make and sell personalized doses or formulations ^[2].

What happens next

The new $675 list price takes effect January 1, 2027, the same day Medicare's negotiated prices begin ^[1][2]. Mercer says a new oral product could launch as soon as April 2026, with three additional injectable weight-loss products possible in 2027, including one from a new manufacturer — competition that could push prices lower still ^[4]. How individual insurance plans translate the lower list price into copays or coinsurance in 2027 is not yet known.